-
1
-
-
84855792427
-
Cancer statistics, 2012
-
PMID:22237781
-
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
84872066969
-
Current concepts and novel targets in advanced pancreatic cancer
-
PMID:23112132
-
Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013; 62:317-26; PMID:23112132; http://dx.doi.org/10.1136/gutjnl-2012-303588.
-
(2013)
Gut
, vol.62
, pp. 317-326
-
-
Michl, P.1
Gress, T.M.2
-
3
-
-
84866450512
-
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion
-
PMID:22969725
-
Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012; 3:270; PMID:22969725.
-
(2012)
Front Physiol
, vol.3
, pp. 270
-
-
Evans, A.1
Costello, E.2
-
4
-
-
84871211965
-
Monoclonal antibodies and other targeted therapies for pancreatic cancer
-
PMID:23187854
-
Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 2012; 18:653-64; PMID:23187854; http://dx.doi. org/10.1097/PPO.0b013e3182758985.
-
(2012)
Cancer J
, vol.18
, pp. 653-664
-
-
Cinar, P.1
Tempero, M.A.2
-
5
-
-
0035056017
-
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
-
PMID:11244047
-
Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-94; PMID:11244047; http://dx.doi.org/10.1146/annurev.immunol.19.1.565.
-
(2001)
Annu Rev Immunol
, vol.19
, pp. 565-594
-
-
Chambers, C.A.1
Kuhns, M.S.2
Egen, J.G.3
Allison, J.P.4
-
6
-
-
33745851479
-
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
-
PMID:16778987
-
Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-45; PMID:16778987; http://dx.doi.org/10.1172/JCI27745.
-
(2006)
J Clin Invest
, vol.116
, pp. 1935-1945
-
-
Quezada, S.A.1
Peggs, K.S.2
Curran, M.A.3
Allison, J.P.4
-
7
-
-
24944459890
-
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
-
PMID:16087944
-
Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6043-6053
-
-
Attia, P.1
Phan, G.Q.2
Maker, A.V.3
Robinson, M.R.4
Quezado, M.M.5
Yang, J.C.6
Sherry, R.M.7
Topalian, S.L.8
Kammula, U.S.9
Royal, R.E.10
-
8
-
-
77950258677
-
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
-
PMID:20143434
-
Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951.
-
(2010)
Cancer
, vol.116
, pp. 1767-1775
-
-
Ku, G.Y.1
Yuan, J.2
Page, D.B.3
Schroeder, S.E.4
Panageas, K.S.5
Carvajal, R.D.6
Chapman, P.B.7
Schwartz, G.K.8
Allison, J.P.9
Wolchok, J.D.10
-
9
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
PMID:20525992
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
10
-
-
79958844438
-
Ipilimumab: first global approval
-
PMID:21668044
-
Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011; 71:1093-104; PMID:21668044; http://dx.doi. org/10.2165/11594010-000000000-00000.
-
(2011)
Drugs
, vol.71
, pp. 1093-1104
-
-
Cameron, F.1
Whiteside, G.2
Perry, C.3
-
11
-
-
77958050577
-
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
-
PMID:20842054
-
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi. org/10.1097/CJI.0b013e3181eec14c.
-
(2010)
J Immunother
, vol.33
, pp. 828-833
-
-
Royal, R.E.1
Levy, C.2
Turner, K.3
Mathur, A.4
Hughes, M.5
Kammula, U.S.6
Sherry, R.M.7
Topalian, S.L.8
Yang, J.C.9
Lowy, I.10
-
12
-
-
84883207410
-
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
-
PMID:23924790
-
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr., Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2.
-
(2013)
J Immunother
, vol.36
, pp. 382-389
-
-
Le, D.T.1
Lutz, E.2
Uram, J.N.3
Sugar, E.A.4
Onners, B.5
Solt, S.6
Zheng, L.7
Diaz Jr., L.A.8
Donehower, R.C.9
Jaffee, E.M.10
-
13
-
-
84886427186
-
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects
-
PMID:23788581
-
Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 2013; 19:5381-9; PMID:23788581; http://dx.doi.org/10.1158/1078-0432.CCR-12-0781.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5381-5389
-
-
Fransen, M.F.1
van der Sluis, T.C.2
Ossendorp, F.3
Arens, R.4
Melief, C.J.5
-
14
-
-
34250871751
-
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses
-
PMID:17575163
-
Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007; 67:5929-39; PMID:17575163; http://dx.doi.org/10.1158/0008-5472.CAN-06-4296.
-
(2007)
Cancer Res
, vol.67
, pp. 5929-5939
-
-
Tuve, S.1
Chen, B.M.2
Liu, Y.3
Cheng, T.L.4
Touré, P.5
Sow, P.S.6
Feng, Q.7
Kiviat, N.8
Strauss, R.9
Ni, S.10
-
15
-
-
44249090471
-
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
-
PMID:18236040
-
Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 2008; 57:1263-70; PMID:18236040; http://dx.doi. org/10.1007/s00262-008-0451-3.
-
(2008)
Cancer Immunol Immunother
, vol.57
, pp. 1263-1270
-
-
Simmons, A.D.1
Moskalenko, M.2
Creson, J.3
Fang, J.4
Yi, S.5
VanRoey, M.J.6
Allison, J.P.7
Jooss, K.8
-
16
-
-
84884271914
-
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
-
PMID:23897981
-
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579.
-
(2013)
J Exp Med
, vol.210
, pp. 1695-1710
-
-
Simpson, T.R.1
Li, F.2
Montalvo-Ortiz, W.3
Sepulveda, M.A.4
Bergerhoff, K.5
Arce, F.6
Roddie, C.7
Henry, J.Y.8
Yagita, H.9
Wolchok, J.D.10
-
17
-
-
84884229186
-
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
-
PMID:23897982
-
Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210:1685-93; PMID:23897982; http://dx.doi.org/10.1084/jem.20130573.
-
(2013)
J Exp Med
, vol.210
, pp. 1685-1693
-
-
Bulliard, Y.1
Jolicoeur, R.2
Windman, M.3
Rue, S.M.4
Ettenberg, S.5
Knee, D.A.6
Wilson, N.S.7
Dranoff, G.8
Brogdon, J.L.9
-
18
-
-
84878936788
-
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
-
Selby MJ. E.J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunology Research 2013; 1:32-42; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013.
-
(2013)
Cancer Immunology Research
, vol.1
, pp. 32-42
-
-
Selby, M.J.E.J.J.1
Quigley, M.2
Henning, K.A.3
Chen, T.4
Srinivasan, M.5
Korman, A.J.6
-
19
-
-
84886405297
-
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity
-
PMID:23965900
-
Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013; 19:5261-3; PMID:23965900; http://dx.doi.org/10.1158/1078-0432.CCR-13-1923.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5261-5263
-
-
Marabelle, A.1
Kohrt, H.2
Levy, R.3
-
20
-
-
84899076438
-
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer
-
Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2014; 2: 80; http://dx.doi.org/10.1158/2326-6066. CIR-13-0067.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 80
-
-
Sandin, L.C.1
Orlova, A.2
Gustafsson, E.3
Ellmark, P.4
Tolmachev, V.5
Tötterman, T.H.6
Mangsbo, S.M.7
-
21
-
-
77954938867
-
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
-
PMID:20445343
-
Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb.
-
(2010)
J Immunother
, vol.33
, pp. 225-235
-
-
Mangsbo, S.M.1
Sandin, L.C.2
Anger, K.3
Korman, A.J.4
Loskog, A.5
Tötterman, T.H.6
-
22
-
-
0035903324
-
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
-
PMID:11560997
-
Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32; PMID:11560997; http://dx.doi.org/10.1084/jem.194.6.823.
-
(2001)
J Exp Med
, vol.194
, pp. 823-832
-
-
Sutmuller, R.P.1
van Duivenvoorde, L.M.2
van Elsas, A.3
Schumacher, T.N.4
Wildenberg, M.E.5
Allison, J.P.6
Toes, R.E.7
Offringa, R.8
Melief, C.J.9
-
23
-
-
51349165526
-
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
-
PMID:18523152
-
Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008; 112:1175-83; PMID:18523152; http://dx.doi. org/10.1182/blood-2007-11-125435.
-
(2008)
Blood
, vol.112
, pp. 1175-1183
-
-
Kavanagh, B.1
O'Brien, S.2
Lee, D.3
Hou, Y.4
Weinberg, V.5
Rini, B.6
Allison, J.P.7
Small, E.J.8
Fong, L.9
-
24
-
-
77749279776
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
-
PMID:20160101
-
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 4275-4280
-
-
Curran, M.A.1
Montalvo, W.2
Yagita, H.3
Allison, J.P.4
-
25
-
-
79955785050
-
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production
-
PMID:21559358
-
Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; PMID:21559358; http://dx.doi.org/10.1371/journal. pone.0019499.
-
(2011)
PLoS One
, vol.6
-
-
Curran, M.A.1
Kim, M.2
Montalvo, W.3
Al-Shamkhani, A.4
Allison, J.P.5
-
26
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
-
PMID:9196156
-
rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13; PMID:9196156.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
-
27
-
-
0034679567
-
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation
-
PMID:10899916
-
Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302; PMID:10899916; http://dx.doi. org/10.1084/jem.192.2.295.
-
(2000)
J Exp Med
, vol.192
, pp. 295-302
-
-
Read, S.1
Malmström, V.2
Powrie, F.3
-
28
-
-
0037446531
-
Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells
-
PMID:12682220
-
Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170:3939-43; PMID:12682220.
-
(2003)
J Immunol
, vol.170
, pp. 3939-3943
-
-
Mottet, C.1
Uhlig, H.H.2
Powrie, F.3
-
29
-
-
77249137663
-
Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease
-
PMID:19936899
-
Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol 2010; 30:80-9; PMID:19936899; http://dx.doi. org/10.1007/s10875-009-9345-1.
-
(2010)
J Clin Immunol
, vol.30
, pp. 80-89
-
-
Eastaff-Leung, N.1
Mabarrack, N.2
Barbour, A.3
Cummins, A.4
Barry, S.5
-
30
-
-
75249100054
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
-
PMID:20004617
-
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1.
-
(2010)
Lancet Oncol
, vol.11
, pp. 155-164
-
-
Wolchok, J.D.1
Neyns, B.2
Linette, G.3
Negrier, S.4
Lutzky, J.5
Thomas, L.6
Waterfield, W.7
Schadendorf, D.8
Smylie, M.9
Guthrie Jr., T.10
-
31
-
-
84876678701
-
Lowdose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
-
PMID:23233419
-
Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin AV. Lowdose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013; 133:98-107; PMID:23233419; http://dx.doi.org/10.1002/ijc.27990.
-
(2013)
Int J Cancer
, vol.133
, pp. 98-107
-
-
Shevchenko, I.1
Karakhanova, S.2
Soltek, S.3
Link, J.4
Bayry, J.5
Werner, J.6
Umansky, V.7
Bazhin, A.V.8
-
32
-
-
34248172651
-
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo
-
PMID:17315190
-
Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121:95-105; PMID:17315190; http://dx.doi.org/10.1002/ijc.22607.
-
(2007)
Int J Cancer
, vol.121
, pp. 95-105
-
-
Grauer, O.M.1
Nierkens, S.2
Bennink, E.3
Toonen, L.W.4
Boon, L.5
Wesseling, P.6
Sutmuller, R.P.7
Adema, G.J.8
-
33
-
-
75149139044
-
Combination of CTLassociated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer
-
PMID:20384858
-
Saha A, Chatterjee SK. Combination of CTLassociated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol 2010; 71:70-82; PMID:20384858; http://dx.doi. org/10.1111/j.1365-3083.2009.02355.x.
-
(2010)
Scand J Immunol
, vol.71
, pp. 70-82
-
-
Saha, A.1
Chatterjee, S.K.2
-
34
-
-
68149155982
-
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
-
PMID:19581407
-
Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; http://dx.doi.org/10.1084/jem.20082492.
-
(2009)
J Exp Med
, vol.206
, pp. 1717-1725
-
-
Peggs, K.S.1
Quezada, S.A.2
Chambers, C.A.3
Korman, A.J.4
Allison, J.P.5
|